
Biocon achieves settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US
Biocon Biologics announced it has reached a settlement and license agreement with Regeneron Pharmaceuticals, Inc to commercialize aflibercept-jbvf (Yesafili), an interchangeable biosimilar to aflibercept, in the US. Biocon and Regeneron executed the …